Related references
Note: Only part of the references are listed.High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study
Sara van Gennep et al.
INFLAMMATORY BOWEL DISEASES (2021)
Longitudinal Trajectory of Fatigue in Patients With Inflammatory Bowel Disease: A Prospective Study
Nienke Z. Borren et al.
INFLAMMATORY BOWEL DISEASES (2021)
Inflammatory bowel disease patients provide reliable self-reported medical information: A multicentre prospective pharmacovigilance monitoring system
Pepijn W. A. Thomas et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2021)
Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel disease
Michiel E. de Jong et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2021)
Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry
Eline L. Giraud et al.
DRUG SAFETY (2021)
Work productivity loss is determined by fatigue and reduced quality of life in employed inflammatory bowel disease patients: a prospective multicentre cohort study
Sara van Gennep et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2021)
Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study
Nienke Z. Borren et al.
JOURNAL OF CROHNS & COLITIS (2020)
Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients
M. E. de Jong et al.
JOURNAL OF CROHNS & COLITIS (2020)
Adalimumab Effectiveness Up to Six Years in Adalimumab-naive Patients with Crohn's Disease: Results of the PYRAMID Registry
Edward V. Loftus et al.
INFLAMMATORY BOWEL DISEASES (2019)
Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part I
Simon R. Knowles et al.
INFLAMMATORY BOWEL DISEASES (2018)
Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study
Mary Kaye Willian et al.
JOURNAL OF PATIENT-REPORTED OUTCOMES (2018)
Patient-reported Outcomes in a French Nationwide Survey of Inflammatory Bowel Disease Patients
Nicolas Williet et al.
JOURNAL OF CROHNS & COLITIS (2017)
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA
Simon Travis et al.
JOURNAL OF CROHNS & COLITIS (2017)
Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease
Lieke M. Spekhorst et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up
Mirthe E. van der Valk et al.
PLOS ONE (2016)
The iMTA Productivity Cost Questionnaire A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses
Clazien Bouwmans et al.
VALUE IN HEALTH (2015)
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
Laurent Peyrin-Biroulet et al.
GUT (2014)
Sick leave and disability pension in inflammatory bowel disease: A systematic review
Katharina Busch et al.
JOURNAL OF CROHNS & COLITIS (2014)
Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study
Marte Lie Hoivik et al.
GUT (2013)
The burden of inflammatory bowel disease in Europe
Johan Burisch et al.
JOURNAL OF CROHNS & COLITIS (2013)
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial
Edouard Louis et al.
JOURNAL OF CROHNS & COLITIS (2013)
European consensus on the histopathology of inflammatory bowel disease
F. Magro et al.
JOURNAL OF CROHNS & COLITIS (2013)
Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population
Christina Ha et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation
Judith E. Baars et al.
INFLAMMATORY BOWEL DISEASES (2012)
Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial
Remo Panaccione et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY (2011)
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy
S. Lichtiger et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Fatigue and Health-related Quality of Life in Inflammatory Bowel Disease: Results from a Population-Based Study in the Netherlands: The IBD-South Limburg Cohort
M. J. L. Romberg-Camps et al.
INFLAMMATORY BOWEL DISEASES (2010)
Permanent work disability in Crohn's disease
Ashwin N. Ananthakrishnan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease
Margaret C. Reilly et al.
CLINICAL THERAPEUTICS (2008)
Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease
T Bernklev et al.
INFLAMMATORY BOWEL DISEASES (2006)
Health-related lost productive time (LPT): Recall interval and bias in LPT estimates
WF Stewart et al.
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE (2004)
Share Paper
